Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The Company’s pipeline focuses in three strategic therapeutic areas (STArs): genetic medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; cardio-metabolic disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, and hepatic infectious disease, with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases. Its products include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), ALN-AT3, ALN-CC5, ALN-AS1, ALN-AAT, ALN-GO1, ALN-TMP, ALN-PCS, ALN-PCSsc, ALN-AC3, ALN-ANG, ANGPTL3, ALN-HBV, ALN-HDV and ALN-PDL. It is developing two investigational RNAi therapeutic candidates for TTR-Mediated Amyloidosis (ATTR): patisiran and revusiran.

Type
Public
HQ
Cambridge, US
Founded
2002
Size (employees)
514 (est)
Alnylam Pharmaceuticals was founded in 2002 and is headquartered in Cambridge, US
Report incorrect company information

Key People/Management at Alnylam Pharmaceuticals

John Maraganore

John Maraganore

Chief Executive Officer
Manmeet Soni

Manmeet Soni

Chief Financial Officer
Barry Greene

Barry Greene

President
Yvonne Greenstreet

Yvonne Greenstreet

Chief Operating Officer
Pushkal Garg

Pushkal Garg

Chief Medical Officer
Akshay Vaishnaw

Akshay Vaishnaw

PRESIDENT, Research & Development
Show more

Alnylam Pharmaceuticals Office Locations

Alnylam Pharmaceuticals has offices in Zug, Windsor and Maidenhead and Cambridge
Cambridge, US (HQ)
300 Third St
Zug, CH
19 Dammstrasse
Windsor and Maidenhead, GB
Braywick Rd
Show all (3)
Report incorrect company information

Alnylam Pharmaceuticals Financials and Metrics

Alnylam Pharmaceuticals Financials

USD

Net income (FY, 2017)

(490.9 m)

EBIT (FY, 2017)

(500.1 m)

Market capitalization (25-Apr-2018)

8.5 b

Cash (31-Dec-2017)

645.4 m

EV

7.9 b
Alnylam Pharmaceuticals's current market capitalization is $8.5 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

General and administrative expense

89.4 b199.4 m

R&D expense

382.4 b390.6 m

Operating expense total

471.7 b590 m

EBIT

(92.9 m)(405 m)(296 m)(424.6 b)(500.1 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

General and administrative expense

6.8 m8.9 m11.5 m9.9 m12.7 m14.6 m16 m21.1 m18 m22.4 m38.5 m45.8 m

R&D expense

34.5 m43.8 m44.7 m46.3 m58 m67 m68.6 m96.3 m83.2 m97.9 m87 m90.6 m

Operating expense total

41.2 m277.3 m52.3 m56.2 m70.8 m81.6 m84.7 m117.4 m101.2 m120.3 m125.5 m136.4 m

EBIT

(32.2 m)(269.1 m)(45 m)(45.2 m)(52.2 m)(72.9 m)(78.3 m)(110 m)(92.5 m)(106.7 m)(106.5 m)(120.5 m)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

53.2 m75.2 m180.9 m193.6 m645.4 m

Accounts Receivable

17.9 m

Inventories

3.9 m9.7 m16.6 m21.7 m

Current Assets

254 m746.4 m1.1 b671.9 m1.8 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

11.8 m350.6 m80.7 m82.7 m306.6 m151.3 m149.2 m231.3 m271.1 m168.5 m171.1 m408.7 m

Current Assets

199.2 m674.1 m665.1 m643 m1.1 b1 b1 b1.1 b888.1 m747.6 m597.2 m960.7 m

PP&E

17 m15.7 m17 m18.8 m21.2 m25.2 m26.3 m36.8 m55.4 m74.2 m130 m147.5 m

Total Assets

447.5 m1.1 b1 b986.4 m1.6 b1.5 b1.4 b1.3 b1.4 b1.3 b1.1 b1.4 b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(89.2 m)(360.4 m)(290.1 m)(410.1 m)(490.9 m)

Depreciation and Amortization

10.2 m11.9 m19.1 m15.1 m13.4 m

Inventories

Accounts Payable

1.8 m8.8 m1.7 m10.1 m(4.9 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(29.7 m)(250.9 m)(44.1 m)(44 m)(50.8 m)(71.8 m)(76.8 m)(103 m)(90.1 m)(104.1 m)(107.3 m)

Accounts Payable

6.2 m5.2 m15.5 m15.7 m14.3 m17.4 m12.8 m23.1 m25.4 m
USDY, 2017

EV/EBIT

-15.9 x

EV/CFO

-20.7 x

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information